Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Aug 12:14:249.
doi: 10.1186/1745-6215-14-249.

Dexamethasone reduces emesis after major gastrointestinal surgery (DREAMS)

Emma Hamilton  1 , Reena Ravikumar, David Bartlett, Elizabeth Hepburn, Mei-Ju Hwang, Nazzia Mirza, Sandeep S Bahia, Anthony Wilkey, Helen Bodenham Chilton, Kelly Handley, Laura Magill, Dion Morton; West Midlands Research Collaborative
Affiliations
Clinical Trial

Dexamethasone reduces emesis after major gastrointestinal surgery (DREAMS)

Emma Hamilton et al. Trials. .

Abstract

Background: Postoperative nausea and vomiting is one of the most common complications affecting patients after surgery and causes significant morbidity and increased length of hospital stay. It is accepted that patients undergoing surgery on the bowel are at a higher risk. In the current era of minimally invasive colorectal surgery combined with enhanced recovery, reducing the incidence and severity of postoperative nausea and vomiting is particularly important. Dexamethasone is widely, but not universally used. It is known to improve appetite and gastric emptying, thus reduce vomiting. However, this benefit is not established in patients undergoing bowel surgery, and dexamethasone has possible side effects such as increased risk of wound infection and anastomotic leak that could adversely affect recovery.

Design: DREAMS is a phase III, double-blind, multicenter, randomized controlled trial with the primary objective of determining if preoperative dexamethasone reduces postoperative nausea and vomiting in patients undergoing elective gastrointestinal resections. DREAMS aims to randomize 1,350 patients over 2.5 years.Patients undergoing laparoscopic or open colorectal resections for malignant or benign pathology are randomized between 8 mg intravenous dexamethasone and control (no dexamethasone). All patients are given one additional antiemetic at the time of induction, prior to randomization. Both the patient and their surgeon are blinded as to the treatment arm.Secondary objectives of the DREAMS trial are to determine whether there are other measurable benefits during recovery from surgery with the use of dexamethasone, including quicker return to oral diet and reduced length of stay. Health-related quality of life, fatigue and risks of infections will be investigated.

Trial registration: ISRCTN21973627.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial design and patient journey. IV, intravenous; QoL, quality of life.
See this image and copyright information in PMC

References

    1. Macario A, Weigner M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999;89(3):652–658. - PubMed
    1. Gan P. Risk factors for PONV. Anesth Analg. 2006;102(6):1884–1898. doi: 10.1213/01.ANE.0000219597.16143.4D. - DOI - PubMed
    1. Apfel C, Kranke P, Eberhart L, Roos A, Roewer N. Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesthes. 2002;88(2):234–240. doi: 10.1093/bja/88.2.234. - DOI - PubMed
    1. Kehlet H, Wilmore D. Evidence based surgical care and the evolution of fast track surgery. Ann Surg. 2008;248(2):189–198. doi: 10.1097/SLA.0b013e31817f2c1a. - DOI - PubMed
    1. Kehlet H, Dahl JB. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet. 2003;362:1921–1928. doi: 10.1016/S0140-6736(03)14966-5. - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources